Literature DB >> 12032231

Expression of complement regulating factors in gastric cancer cells.

T Inoue1, M Yamakawa, T Takahashi.   

Abstract

AIMS: To investigate the deposition of complement components, C3d and C5b-9, and the expression of complement regulating factors (S protein, membrane cofactor protein (MCP; CD46), protectin (CD59), decay accelerating factor (DAF; CD55), and type 1 complement receptor (CR1; CD35)) in gastric cancers.
METHODS: Specimens of gastric cancer were examined by immunohistochemistry and immunoelectron microscopy.
RESULTS: Four complement regulating factors (S protein, MCP, protectin, and DAF) were expressed on gastric cancer cells, in ultrastructurally localised areas on the cell membrane. CR1 was not expressed. The staining intensity of DAF in both differentiated and undifferentiated adenocarcinomas was significantly higher than in histologically normal gastric epithelium. Furthermore, the staining intensity of DAF in gastric cancers showing a diffusely infiltrating growth pattern was higher than in gastric cancers showing an expanding growth pattern.
CONCLUSIONS: These data indicate that DAF may play a role in cancer cell infiltration and resistance in tumour cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12032231      PMCID: PMC1187173          DOI: 10.1136/mp.55.3.193

Source DB:  PubMed          Journal:  Mol Pathol        ISSN: 1366-8714


  23 in total

1.  Membrane cofactor protein (MCP; CD46): isoform-specific tyrosine phosphorylation.

Authors:  G Wang; M K Liszewski; A C Chan; J P Atkinson
Journal:  J Immunol       Date:  2000-02-15       Impact factor: 5.422

2.  Protection of human breast cancer cells from complement-mediated lysis by expression of heterologous CD59.

Authors:  J Yu; T Caragine; S Chen; B P Morgan; A B Frey; S Tomlinson
Journal:  Clin Exp Immunol       Date:  1999-01       Impact factor: 4.330

3.  Control of C3b and C5b deposition by CD46 (membrane cofactor protein) after alternative but not classical complement activation.

Authors:  P Devaux; D Christiansen; M Fontaine; D Gerlier
Journal:  Eur J Immunol       Date:  1999-03       Impact factor: 5.532

4.  Characterization of glycosylphosphatidylinositol-linked molecule CD55/decay-accelerating factor as the receptor for antibody SC-1-induced apoptosis.

Authors:  F Hensel; R Hermann; C Schubert; N Abé; K Schmidt; A Franke; A Shevchenko; M Mann; H K Müller-Hermelink; H P Vollmers
Journal:  Cancer Res       Date:  1999-10-15       Impact factor: 12.701

5.  Complement activation and expression of membrane regulators in the middle ear mucosa in otitis media with effusion.

Authors:  M Närkiö-Mäkelä; J Jero; S Meri
Journal:  Clin Exp Immunol       Date:  1999-06       Impact factor: 4.330

6.  Complement-mediated killing of microtumors in vitro.

Authors:  J Hakulinen; S Meri
Journal:  Am J Pathol       Date:  1998-09       Impact factor: 4.307

7.  The cytoplasmic domains of complement regulatory protein CD46 interact with multiple kinases in macrophages.

Authors:  T C Wong; S Yant; B J Harder; J Korte-Sarfaty; A Hirano
Journal:  J Leukoc Biol       Date:  1997-12       Impact factor: 4.962

8.  Expression of the complement regulatory proteins decay accelerating factor (DAF, CD55), membrane cofactor protein (MCP, CD46) and CD59 in the normal human uterine cervix and in premalignant and malignant cervical disease.

Authors:  K L Simpson; A Jones; S Norman; C H Holmes
Journal:  Am J Pathol       Date:  1997-11       Impact factor: 4.307

9.  Human lung cancer cell lines express cell membrane complement inhibitory proteins and are extremely resistant to complement-mediated lysis; a comparison with normal human respiratory epithelium in vitro, and an insight into mechanism(s) of resistance.

Authors:  S Varsano; L Rashkovsky; H Shapiro; D Ophir; T Mark-Bentankur
Journal:  Clin Exp Immunol       Date:  1998-08       Impact factor: 4.330

10.  Targeting of functional antibody-CD59 fusion proteins to a cell surface.

Authors:  H F Zhang; J Yu; E Bajwa; S L Morrison; S Tomlinson
Journal:  J Clin Invest       Date:  1999-01       Impact factor: 14.808

View more
  14 in total

1.  RNA interference characterization of proteins discovered by proteomic analysis of pancreatic cancer reveals function in cell growth and survival.

Authors:  Candy N Lee; Jenny L Heidbrink; Katherine McKinnon; Victoria Bushman; Henrik Olsen; William FitzHugh; Aiqun Li; Karen Van Orden; Tao He; Steven M Ruben; Paul A Moore
Journal:  Pancreas       Date:  2012-01       Impact factor: 3.327

Review 2.  Membrane attack by complement: the assembly and biology of terminal complement complexes.

Authors:  Cosmin A Tegla; Cornelia Cudrici; Snehal Patel; Richard Trippe; Violeta Rus; Florin Niculescu; Horea Rus
Journal:  Immunol Res       Date:  2011-10       Impact factor: 2.829

Review 3.  Role of C5b-9 complement complex and response gene to complement-32 (RGC-32) in cancer.

Authors:  Sonia I Vlaicu; Cosmin A Tegla; Cornelia D Cudrici; Jacob Danoff; Hassan Madani; Adam Sugarman; Florin Niculescu; Petru A Mircea; Violeta Rus; Horea Rus
Journal:  Immunol Res       Date:  2013-05       Impact factor: 2.829

4.  Suppression of tumorigenesis: modulation of inflammatory cytokines by oral administration of microencapsulated probiotic yogurt formulation.

Authors:  Aleksandra Malgorzata Urbanska; Arghya Paul; Jasmine Bhathena; Jasmine Bhahena; Satya Prakash
Journal:  Int J Inflam       Date:  2010-10-31

5.  The invasion and metastasis promotion role of CD97 small isoform in gastric carcinoma.

Authors:  Daren Liu; Bogusz Trojanowicz; Longyun Ye; Chao Li; Luqing Zhang; Xiaowen Li; Guogang Li; Yixiong Zheng; Li Chen
Journal:  PLoS One       Date:  2012-06-29       Impact factor: 3.240

Review 6.  Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer.

Authors:  Saskia Meyer; Jeanette H W Leusen; Peter Boross
Journal:  MAbs       Date:  2014-10-30       Impact factor: 5.857

7.  Prognostic Significance of Preoperative and Postoperative Complement C3 Depletion in Gastric Cancer: A Three-Year Survival Investigation.

Authors:  Jinning Ye; Yufeng Ren; Jianhui Chen; Wu Song; Chuangqi Chen; Shirong Cai; Min Tan; Yujie Yuan; Yulong He
Journal:  Biomed Res Int       Date:  2017-09-14       Impact factor: 3.411

Review 8.  Beyond the Role of CD55 as a Complement Component.

Authors:  So Hee Dho; Jae Cheong Lim; Lark Kyun Kim
Journal:  Immune Netw       Date:  2018-02-20       Impact factor: 5.851

9.  Development of a radionuclide-labeled monoclonal anti-CD55 antibody with theranostic potential in pleural metastatic lung cancer.

Authors:  So Hee Dho; Soo Yong Kim; Chaeuk Chung; Eun Ha Cho; So-Young Lee; Ji Young Kim; Lark Kyun Kim; Sung-Won Min; Jichul Lee; Sung Hee Jung; Jae Cheong Lim
Journal:  Sci Rep       Date:  2018-06-12       Impact factor: 4.379

Review 10.  Mechanisms of Therapeutic Antitumor Monoclonal Antibodies.

Authors:  Li-Chung Tsao; Jeremy Force; Zachary C Hartman
Journal:  Cancer Res       Date:  2021-06-18       Impact factor: 13.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.